Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1993 1
1994 1
1996 2
1997 2
1998 4
1999 7
2000 3
2001 3
2002 1
2003 1
2004 6
2005 14
2006 12
2007 17
2008 20
2009 13
2010 14
2011 21
2012 25
2013 28
2014 15
2015 13
2016 14
2017 15
2018 14
2019 12
2020 19
2021 29
2022 25
2023 21
2024 20
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

359 results

Results by year

Filters applied: . Clear all
Page 1
Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers.
Lowery FJ, Krishna S, Yossef R, Parikh NB, Chatani PD, Zacharakis N, Parkhurst MR, Levin N, Sindiri S, Sachs A, Hitscherich KJ, Yu Z, Vale NR, Lu YC, Zheng Z, Jia L, Gartner JJ, Hill VK, Copeland AR, Nah SK, Masi RV, Gasmi B, Kivitz S, Paria BC, Florentin M, Kim SP, Hanada KI, Li YF, Ngo LT, Ray S, Shindorf ML, Levi ST, Shepherd R, Toy C, Parikh AY, Prickett TD, Kelly MC, Beyer R, Goff SL, Yang JC, Robbins PF, Rosenberg SA. Lowery FJ, et al. Science. 2022 Feb 25;375(6583):877-884. doi: 10.1126/science.abl5447. Epub 2022 Feb 3. Science. 2022. PMID: 35113651 Free PMC article.
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers.
Yossef R, Krishna S, Sindiri S, Lowery FJ, Copeland AR, Gartner JJ, Parkhurst MR, Parikh NB, Hitscherich KJ, Levi ST, Chatani PD, Zacharakis N, Levin N, Vale NR, Nah SK, Dinerman A, Hill VK, Ray S, Bera A, Levy L, Jia L, Kelly MC, Goff SL, Robbins PF, Rosenberg SA. Yossef R, et al. Cancer Cell. 2023 Dec 11;41(12):2154-2165.e5. doi: 10.1016/j.ccell.2023.11.005. Epub 2023 Nov 30. Cancer Cell. 2023. PMID: 38039963 Free PMC article.
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.
Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, Gartner J, Jia L, Trebska-McGowan K, Somerville RP, Robbins PF, Rosenberg SA, Goff SL, Feldman SA. Zacharakis N, et al. Nat Med. 2018 Jun;24(6):724-730. doi: 10.1038/s41591-018-0040-8. Epub 2018 Jun 4. Nat Med. 2018. PMID: 29867227 Free PMC article. Clinical Trial.
Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.
Kim SP, Vale NR, Zacharakis N, Krishna S, Yu Z, Gasmi B, Gartner JJ, Sindiri S, Malekzadeh P, Deniger DC, Lowery FJ, Parkhurst MR, Ngo LT, Ray S, Li YF, Hill V, Florentin M, Masi RV, Paria BC, Levin N, Bera A, Hedges EA, Choi A, Chatani PD, Parikh AY, Levi S, Seitter S, Lu YC, Zheng Z, Prickett TD, Jia L, Hernandez JM, Hoang CD, Robbins PF, Goff SL, Sherry RM, Yang JC, Rosenberg SA. Kim SP, et al. Cancer Immunol Res. 2022 Aug 3;10(8):932-946. doi: 10.1158/2326-6066.CIR-22-0040. Cancer Immunol Res. 2022. PMID: 35749374 Free PMC article.
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes.
Levin N, Kim SP, Marquardt CA, Vale NR, Yu Z, Sindiri S, Gartner JJ, Parkhurst M, Krishna S, Lowery FJ, Zacharakis N, Levy L, Prickett TD, Benzine T, Ray S, Masi RV, Gasmi B, Li Y, Islam R, Bera A, Goff SL, Robbins PF, Rosenberg SA. Levin N, et al. J Immunother Cancer. 2024 May 30;12(5):e008645. doi: 10.1136/jitc-2023-008645. J Immunother Cancer. 2024. PMID: 38816232 Free PMC article.
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results.
Parkhurst M, Goff SL, Lowery FJ, Beyer RK, Halas H, Robbins PF, Prickett TD, Gartner JJ, Sindiri S, Krishna S, Zacharakis N, Ngo L, Ray S, Bera A, Shepherd R, Levin N, Kim SP, Copeland A, Nah S, Levi S, Parikh N, Kwong MLM, Klemen ND, Yang JC, Rosenberg SA. Parkhurst M, et al. Nat Med. 2024 Sep;30(9):2586-2595. doi: 10.1038/s41591-024-03109-0. Epub 2024 Jul 11. Nat Med. 2024. PMID: 38992129 Clinical Trial.
PDE-5 Inhibitors for BPH-Associated LUTS.
Brousil P, Shabbir M, Zacharakis E, Sahai A. Brousil P, et al. Curr Drug Targets. 2015;16(11):1180-6. doi: 10.2174/138945011611151013164756. Curr Drug Targets. 2015. PMID: 26470799 Review.
359 results